Abstract: The present invention provides a prophylactic or therapeutic agent for various malignant tumors, including currently intractable solid tumors, which contains a novel antibody having the ability to bind to human LAT1/CD98 and inducing antibody-dependent cellular cytotoxicity specifically against cancer cells as an active ingredient.

Abstract: The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and/or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.

Abstract: A method for direct therapeutic treatment of myocardial tissue in a localized region of a heart having a pathological condition. The method includes identifying a target region of the myocardium and applying material directly and substantially only to at least a portion of the myocardial tissue of the target region. The material applied results in a physically modification the mechanical properties, including stiffness, of said tissue. Various devices and modes of practicing the method are disclosed for stiffening, restraining and constraining myocardial tissue for the treatment of conditions including myocardial infarction or mitral valve regurgitation.

Abstract: A method for diagnosing the development of a tissue injury in a subject comprising administering a sample of neoantibodies to the subject's tissue for the purpose of detecting the presence of neoepitopes bearing complement proteins.

Abstract: The present invention relates to a method of differentially diagnosing different types of dementia. In particular, the method relates to the use of specific SPECT tracers for differentially diagnosing Alzheimer's disease, Lewy-Body Dementia, and Frontotemporal Dementia.

Abstract: Embodiments relate to an ophthalmology microscopy-system and a method of operating an ophthalmology microscopy-system which allow for an at least partial or full removal of liquids and gels used in ophthalmology for application in an eye of a patient in an particularly efficient way. Further embodiments relate to a product such as a liquid or a gel usable for an application in an eye of a patient, wherein the product has a high transmittance and, nevertheless, may be made visible particularly well.

Abstract: A composition of a bone repair mixture has a quantity of allograft particulate bone having a bone particle distribution of particle sizes less than 700 micron and a quantity of biologic carrier material intermixed with the particulate bone. The biologic carrier material is one of fascia, deep fascia or a fascia mixture. Preferably, the carrier material is exclusively fascia lata.

Abstract: A contrast agent for angiography is disclosed, in particular, for examining animal or human bodies or components thereof such as members or organs thereof, comprising an essentially oil-based apolar contrast component for X-ray examinations, the contrast component having a contrast component viscosity in the range of 30-100 mPas. The contrast agent is characterized in that the contrast component is present in a mixture with at least one further apolar component, the viscosity of which is less than or at most equal to the contrast component viscosity. Methods for angiography examination are also disclosed, in which such a contrast agent or also a polar contrast agent are used at least periodically and applications of such contrast agents.

Abstract: PSMA ligands, compositions, and methods therefore are disclosed where the ligand is a peptide having the sequence X1X2CVEVX3QNSCX4X5 where X1-X5 are independently a natural or non-natural amino acid or a peptide having the sequence CALCEFLG [SEQ ID NO: 1]. Especially preferred aspects include diagnostic reagents for detection and/or quantification of PSMA in a sample, therapeutic reagents, and diagnostic imaging reagents.

Abstract: In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human FOXC1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that produces a FOXC1 monoclonal antibody which binds an antigenic peptide sequence of human FOXC1 as described above is also provided.

Abstract: The invention relates to a method of 13C-MR detection using an imaging medium comprising hyperpolarised 13C-fructose and to an imaging medium containing hyperpolarised 13C-fructose for use in said method.

Abstract: The invention relates to a method for targeting an imaging agent to cells of an animal to detect localized infections. More particularly, localized infections are detected by targeting imaging agents to inflammatory cells having receptors for a vitamin by using vitamin-imaging agent conjugates.

Abstract: The present invention relates to novel heteroaryl substituted benzothiazole derivatives, precursors thereof, and therapeutic uses for such compounds, having the structural formula (I) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzothiazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.

Abstract: The invention described herein relates to the detection, diagnosis, and treatment of intestinal metaplasias that develop to esophageal, gastric, and pancreatic adenocarcinoma. The stem cells and differentiated cells of these intestinal metaplasias show high expression of CDH17 as well as other proteins. The invention also includes a clonal population of Barrett's esophagus stem cells as well as the stem cells of the surrounding normal epithelia and methods of using them for the detection, diagnosis, and treatment of Barrett's esophagus.

Abstract: According to one embodiment, a contrast agent includes a blood vessel contrast enhancement particles configured to enhance contrast of a blood vessel of an object and a diseased tissue contrast enhancement particles configured to enhance contrast of a diseased tissue of the object. The blood vessel contrast enhancement particles have a first particle size larger than a gap of vascular endothelial cells under an EPR effect. The diseased tissue contrast enhancement particles have a second particle size smaller than the gap.

Abstract: This invention relates to diazabicyclononyl oxadiazolyl derivatives, which are found to-be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. Ar1 represents a pyrrolyl group, optionally substituted with alkyl or halo-alkyl.

Abstract: A method for treating prostate related diseases in a subject, the method comprising i) optionally administering to subject an initial boost dose of one or more active substances and/or prodrugs, and ii) administering locally into the prostate a controlled release pharmaceutical composition comprising one or more active substances in a biodegradable ceramic carrier. The biodegradable hydrating ceramic may be selected from the group consisting of non-hydrated or hydrated calcium sulphate, calcium phosphate, calcium carbonate, calcium fluoride, calcium silicate, magnesium sulphate, magnesium phosphate, magnesium carbonate, magnesium fluoride, magnesium silicate, barium sulphate, barium phosphate, barium carbonate, barium fluoride, barium silicate, or mixtures thereof. In a specific embodiment, the biodegradable hydrating ceramic is non-hydrated or hydrated calcium sulphate.

Abstract: A composition of a bone repair mixture has a quantity of allograft particulate bone having a bone particle distribution of particle sizes less than 700 micron and a quantity of biologic carrier material intermixed with the particulate bone. The biologic carrier material is one of fascia, deep fascia or a fascia mixture. Preferably, the carrier material is exclusively fascia lata.

Abstract: The present invention provides targeted delivery compositions and methods of using the compositions for treating and diagnosing a disease state in a subject.

Abstract: The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing two linked iodinated phenyl groups of the general formula R—N(CHO)—X—N(R3)—R wherein X denoted an optionally substituted alkylene group, R3 denotes a hydrogen atom or an acyl function and each R denotes a triiodinated phenyl residue further substituted by hydrophilic moieties. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging, and to contrast media containing such compounds.

Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.

Abstract: Disclosed are compositions that contain a plurality of biocompatible self-assembling molecules that transform from isolated molecules or spherical micelles in the circulation into cylindrical nanofibers in the acidic extracellular environment of tumors which can be used to achieve a higher relative concentration of imaging, drug delivery, or radiotherapeutic agents at the tumor site compared to non-tumor tissues. This transition is rapid and reversible, indicating the system is in thermodynamic equilibrium.

Abstract: The invention provides compositions and method for delivering a therapeutic or diagnostic agent to a disease site in a mammal, the method comprising administering to the mammal a therapeutically or diagnostically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises the therapeutic or diagnostic agent coupled to a Procaspase 8 polypeptide and a pharmaceutically acceptable carrier.

Abstract: Provided are a contrast agent for contrast imaging lymph node, which includes iron oxide nanoparticles dispersed and stabilized in an aqueous medium by a mussel adhesive protein-mimetic copolymer, a method for contrast enhanced lymphography using the foregoing contrast agent, and a method for diagnosis of lymph node cancers using the foregoing contrast agent. Using such a mussel adhesive protein-mimetic copolymer, the surface of iron oxide is modified and dispersed well in water to prepare a colloidal solution, which in turn forms the contrast agent containing the colloidal solution. The inventive contrast agent does not have toxicity and is easily taken up to the lymph node to exhibit excellent contrast imaging effects. The contrast agent of the present invention is useful for diagnosis of metastatic cancers.

Abstract: The present invention is directed to peptide reagents, methods for detecting colon pre-cancer (dysplasia with non-polypoid or polypoid morphology) or cancer using the peptide reagents, and methods for targeting pre-cancerous or cancerous colon cells using the peptide reagents.

Abstract: The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency. Methods of improving growth and liver function, increasing LAL tissue concentration, and increasing LAL activity in a human patient suffering from LAL deficiency are also provided.

Abstract: The invention relates to pharmaceutical agents containing a particulate inorganic matrix having a diameter of from 0.1 nm to 100 ?m, preferably 1 nm to 10 ?m, particularly preferably 1 nm to 1 ?m, such as, for example, topaz, (Al2F2)[SiO4], and chiolite, Na[Al3F4], preferably wavellite, Al3(PO4)2(OH,F)2, calcium carbonate, CaCO3, maghemite, ?-Fe2O3, particularly preferably zeolites, gen. formula Mn[(AlO2)x(SiO2)y] (M=metal, e.g.

Abstract: The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO).

Abstract: The present invention relates to novel nanoparticles which can be advantageously used in the health sector as diagnostic and/or therapeutic agents. Nanoparticles of the invention comprise a metallic material at least partly covered with an hafnium oxide material or embedded therein. When compared to existing products, these nanoparticles offer a remarkable benefit over risk ratio. Specifically, these nanoparticles potentiate the efficiency of known metallic nanoparticles. Indeed, they retain the metal intrinsic properties and are now in addition safely usable in a mammal, in particular in a human being. The invention also relates to methods for producing said nanoparticles, to compositions containing same, and to uses thereof.

Abstract: It is an object of the present invention to provide a targeting agent that enables drug delivery to a neovascular site and the imaging of such a neovascular site, utilizing the effect of the agent to accumulate in the neovascular site. The present invention provides a targeting agent to a neovascular site, which comprises a gelatin-like protein.

Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.

Abstract: Disclosed is a method for making a colloidal suspension of precious metal nanoparticles. The method comprises providing a target material comprising a precious metal in a liquid dispersion medium in an ablation container. The dispersion medium has an electrical conductivity within a predetermined conductivity range. Laser pulses are used to generate the nanoparticles from the target in the container. While generating the nanoparticles the electrical conductivity of the dispersion medium is monitored and maintained within the predetermined range and thereby the generated nanoparticles are produced within a predetermined size range. The generated nanoparticles are used to form a colloidal suspension.

Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.

Abstract: The present invention provides methods and compositions for the nanotechnology-based therapy of one or more mammalian diseases. Disclosed are gold-in-porous silicon nanoassemblies that are effective in the targeted and localized treatment of one or more human hyperproliferative disorders, including, for example, cancer of the breast. Methods of systemic administration of these nanoassembly vectors are disclosed that facilitate direct thermal ablative therapy of selected tissues using a localized application of near-infrared energy to the target site, wherein the gold-in-porous silicon nanoparticles release heat to destroy the surrounding cancerous tissue.

Abstract: The present invention provides particulate contrast media for use in CT imaging. The contrast media are based on particles of low-Z elements. In an exemplary embodiment, the invention provides an enteric contrast medium formulation. An exemplary formulation comprises, (a) an enteric contrast medium comprising essentially water-insoluble particles of a material selected from microparticles and nanoparticles. Exemplary particles comprise a material comprising a plurality of atoms of an element with an atomic number from 6 to 52. In various embodiments, the particles are coated with a material compatible with enteric administration of the formulation to a subject in need of such administration. In an exemplary embodiment, the contrast medium is incorporated into a pharmaceutically acceptable vehicle in which the particles are suspended.

Abstract: A bioactive PMMA (polymethylmethacrylate) bone cement contains a powder component and a reactive monomer liquid, wherein the powder component and the reactive monomer liquid when mixed with one another react with one another and form a polymer-based solid material. The powder component contains particulate polymer powder of polymethylmethacrylates; a radical starter; and anionic copolymer nanoparticles. The anionic copolymer nanoparticles are distributed in nano-particulate form within the particulate powder component or coated as a film on particles of the particulate polymer powder.

Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.

Abstract: Nanocarriers and methods of preparation and use of nanocarriers are presented. In some embodiments, a nanocarrier composition comprises an organic liquid comprising a plurality of nanoparticles dispersed therein; and a coating material disposed around the exterior surface of the organic liquid. Biological tissue may be imaged or treated by coming into contact with a nanocarrier composition, and, at least in some embodiments, irradiated.

Abstract: The present invention relates to a new diagnostic X-ray composition which exhibits a superior cardiac safety profile. The composition comprises a non-ionic iodinated dimer in a pharmaceutically acceptable carrier. More particularly, the invention provides a diagnostic composition comprising a Compound I, a pharmaceutically acceptable carrier, and dissolved therein a sodium compound and a calcium compound providing a sodium ion concentration of 40-50 mM and a calcium ion concentration of 0.1-0.7 mM. The invention also relates to methods of imaging using such diagnostic compositions.

Abstract: The present invention provides methods and compositions for modulating x-ray attenuation, where the x-ray attenuation compound can comprise a molecule having at least two conformational states, a first k-edge atom attached to the molecule at a first position, and a second k-edge atom attached to the molecule at a second position, where the molecule changes from a first conformational state to a second conformational state in response to an external stimulus. Additionally, a first interatom distance between the first k-edge atom and the second k-edge atom in the first conformational state can be within a first harmonic error of 0 to about 0.2, and a second interatom distance between the first k-edge atom and the second k-edge atom in the second conformational state can be within a second harmonic error of about 0.8 to 1.0.

Abstract: Provided are methods for treating cancer in a patient, comprising administering to a patient in need thereof a therapeutically effective regimen, the regimen comprising administering a gamma-secretase inhibitor, wherein the regimen results in a reduction in the cancer cell population in the patient. In some embodiments of the methods, the therapeutically effective regimen stabilizes, reduces or eliminates the cancer stem cell population. Also provided are compounds of the formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, and X are as herein described.

Abstract: The present invention is to provide a medical tissue-marker which enables the identification of a location even from the outside of an organ, can remain topical over a long period, and enables the easy identification of a marked location within the whole organ; also to provide a manufacturing method for the medical tissue-marker. The medical tissue-marker as in the present invention includes a vesicle formed by the synthesis of a phospholipid and a near infrared fluorescent dye, and an emulsion formed by the synthesis of the phospholipid and an X-ray contrast medium, and has agglomerated clusters wherein the vesicle and the emulsion are contained in a hydrophilic solvent and a plurality of capsules are formed by means of an emulsifier.

Abstract: A special class of drug-depot forming triblock copolymers which are very suitable for the loading, containment and releasing of sensitive drugs such as proteins from biodegradable, injectable drug depots. How to visualize these depots for various imaging related purposes is described. A composition comprising a tri-block copolymer according to formula 1 B-A-B (1), wherein A stands for a linear poly-(ethylene glycol) block and wherein B stands for wherein B stands for a poly(lactide-co-?-caprolactone) block, wherein the hydroxyl end-groups of the tri-block copolymer are at least partially acylated with an optionally substituted acyl having 2 to 12 C-atoms, C-atoms of the substituents included; an active ingredient, preferably a pharmaceutically active ingredient and a solvent, wherein the block ratio of the tri-block copolymer, which ratio is defined as the ratio between the sum of the average molecular weight of the B-blocks and the sum of the average molecular weight of the A-block ranges from 1.4 to 3.5.

Abstract: The method for remote, non-invasive in vivo control of the activation of light-sensitive bioactive molecules for the purpose of research or therapy is based on delivering to the required site of the body of nanoparticles along with said light-sensitive bioactive molecules. Nanoparticles' core is made from scintillator material that absorbs X-ray and in response emits visible light; they have biocompatible protective coating and surface targeting agents enabling accumulation at the required site(s) within the body. Irradiation of the site with the highly penetrable X-rays causes nanoparticles to emit visible light which will activate light-sensitive bioactive molecule(s) within this site inducing sought therapeutic effect.

Abstract: Imaging agents are described that comprise labeled substrates capable of being introduced into cells via the cystine/glutamate antiporter. The substrates may be used for imaging or detecting oxidative stress in cells by introducing the labeled agents into cells via the cystine/glutamate antiporter and subsequent detection.

Abstract: This invention relates to novel compounds suitable for labeling or already labeled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

Abstract: A method of delivering therapy to a target site. The method includes (a) obtaining a base image of the target site, (b) injecting a dose of a mix of a therapeutic agent and a contrast agent into a first injection location at the target site via a needle passing through a catheter, (c) collecting sequential fluoroscopic images of a contrast agent dispersion cloud at the first injection location, (d) determining a contrast agent dispersion area from the sequential fluoroscopic images, (e) determining a therapeutic agent dispersion area from the contrast agent dispersion area, (f) marking the therapeutic agent dispersion area on the base image of the target site, and (g) repeating (b) through (f) until the target site is substantially covered with overlapping therapeutic agent dispersion areas corresponding to a plurality of injections at a plurality of injection locations at the target site.

Abstract: The present invention relates to diagnostic imaging and in particular to the diagnostic imaging and therapy of cancer by means of compositions which specifically target the FSH Receptor expressed by tumor endothelial cells and circulating blood cells.

Abstract: Translocator protein (TSPO) targeting compounds are described. Methods of making the compounds, and uses of the compounds for imaging are also described.

Abstract: There is provided signal modifying compositions for medical imaging comprising a carrier and signal modifying agents specific for two or more imaging modalities. The compositions are characterized by retention efficiency, with respect of the signal modifying agents that enables prolonged contrast imaging without significant depletion of the signal modifying agent from the carrier. The carriers of the present invention are lipid based or polymer based the physico-chemical properties of which can be modified to entrap or chelate different signal modifying agents and mixtures thereof and to target specific organs or tumors or tissues within a mammal.